A study published in the Journal of Clinical Oncology found that smokers have a higher risk of death, disease recurrence, and poorer survival rates compared to non-smokers with head and neck cancer. Researchers highlighted the importance of tobacco cessation and moderation of alcohol use to improve quality of life and survival.
A recent study found that group therapy did not improve survival rates in early-stage breast cancer patients. The researchers, led by David W. Kissane, evaluated the impact of cognitive-existential group therapy (CEGT) on survival and found no significant difference between those receiving CEGT and those not receiving it.
A study has identified two distinct subclasses of liver cancer with differing survival rates, providing new molecular insight into the pathogenesis of hepatocellular carcinoma. The findings suggest that gene expression profiles can accurately predict patient survival and may lead to the development of more targeted therapies.
Using combination therapies that include 6 months of androgen suppression therapy (AST) alongside radiation therapy (RT) improves survival rates for patients with locally advanced prostate cancer. The study found significantly higher survival rates, lower prostate cancer-specific mortality, and a reduced need for salvage AST in the com...
A randomized clinical trial showed that adjuvant chemotherapy and immunotherapy for colon cancer patients offer no disease-free or overall survival benefits after 10 years. The improvements in 5-year survival rates observed in the past have disappeared over time, suggesting that newer chemotherapy regimens may be more effective.
Researchers found that adherence to St-Gallen guidelines improved overall survival at 7 years, especially for those at moderate risk of recurrence. Women whose treatment conformed to guideline recommendations experienced better survival and lower recurrence rates compared to those with non-guideline therapy.
In Harare, Zimbabwe, cancer survival rates are disturbingly low, with black patients facing significantly lower survival rates than white patients. The study's findings highlight the need for better access to early detection and treatment methods.
A study found that physical symptoms, such as shortness of breath and weakness, predict cancer prognosis. Physical health-related quality of life (hrQoL) factors were stronger predictors of survival than psychosocial factors.
A study of 4,537 Olmsted County residents found that heart failure incidence remained stable between 1979 and 2000, but survival rates improved for women. In contrast, men experienced poorer outcomes, with higher incidence rates and lower survival rates.
A vaccine targeting cancer-related antigens in glioblastoma cells appears to prolong patient survival by a median of 103 weeks. The dendritic cell vaccine generated an immune response against these antigens, significantly improving survival rates compared to patients without the treatment.
Cedars-Sinai researchers found that laminin-8 expression is linked to tumor aggressiveness and patient outcomes. High levels of laminin-8 are associated with shorter survival times and increased risk of tumor recurrence.
A new study shows that VELCADE (bortezomib) can significantly extend survival and induce important responses in relapsed and refractory multiple myeloma patients. The median overall survival was 17.2 months, with a 14.1-month duration of response and 15.3-month time to disease progression.
Research challenges previous findings on higher hematocrits achieved through epoetin treatment for end-stage renal disease patients. Cotter's analysis suggests that the current spending on Epogen dosages may not be justified, considering the lack of evidence supporting its survival benefits.
A retrospective study of 110 elderly leukemia patients found similar complete remission and two-year survival rates as younger patients when treated with anthracyclin-based induction chemotherapy. The study's findings suggest that age is not a predictor of survival, but rather the treatment protocol received.
The CAMPTOSAR plus cisplatin regimen demonstrated improved one-year survival rates (59.2%) and response rates (31%) compared to current standard treatments. Patient toxicities were also significantly reduced, with fewer grade 3-4 neutropenia and thrombocytopenia cases.
A Phase III trial found that CAMPTOSAR combinations with select targeted agents improve survival for MCRC patients. The combination of Avastin and IFL yields an average survival of 25.1 months compared to 15.8 months with IFL alone. A Phase II trial also shows the efficacy of Erbitux plus CAMPTOSAR and infusional FOLFIRI in EGFR-expres...
The study found that Tarceva significantly improved overall survival and progression-free survival in patients with advanced NSCLC, with a median survival of 6.7 months compared to 4.7 months in the placebo arm. The treatment also showed improvements in time to symptom deterioration, response rate, and patient survival at one year.
A new breast cancer treatment, gemcitabine with paclitaxel, has been shown to extend overall survival in women with advanced breast cancer. The study found that median overall survival was 18.5 months for the combination therapy, compared to 15.8 months for paclitaxel alone.
The FDA-approved Avastin increases patient survival by almost five months when combined with chemotherapy, showing a 10.6-month progression-free survival rate compared to 6.2 months in the control group.
Researchers found that genetic variations in XPD and XRCC1 genes are associated with decreased median survival in non-small cell lung cancer patients. Patients with more variations in these genes had shorter survival times, with those having no variations surviving the longest.
Researchers have identified a set of six genes that correlate with survival in diffuse large B-cell lymphoma, including LMO2, BCL6, and CCND2. The findings suggest that molecular profiling may help refine prognoses for this difficult-to-treat blood cancer.
Researchers found that African Americans and whites with identical health care coverage experience no racial disparity in colon cancer survival. While subtle differences were seen in treatment options, the study suggests equal access to care can eliminate disparities
A new online tool provides personalized 10-year survival predictions for prostate cancer patients, taking into account age, race, co-morbidities, and treatment type. The model also highlights the significant impact of co-morbidities on long-term survival rates.
Researchers develop a method to identify biologically significant cancer subtypes using gene expression data and patient clinical history, showing it's a powerful predictor of patient survival. The approach reduces the chances of including unrelated genes, increasing the probability of identifying clinically relevant subsets of genes.
A study published in Journal of Clinical Oncology found that extended lymph node dissection does not increase long-term survival among gastric cancer patients, potentially increasing morbidity and hospital mortality. The procedure may only be beneficial if safe and effective alternatives can be developed.
A 10-year study found that laparoscopic surgery for colorectal cancer has the same prognosis as conventional surgery, with a 76% 5-year survival rate. The procedure resulted in shorter postoperative recovery times but longer surgery durations compared to conventional surgery.
A recent study by UT Southwestern Medical Center found that children with sickle cell disease are now living up to 18 years longer than comparable statistics from 30 years ago. Modern treatments, including prophylactic penicillin and hydroxyurea, have significantly improved survival rates.
Olfactory sensory neurons can adapt to odorant stimulation, but the ability to enhance long-term survival after stimulation has been unclear. Researchers found that odorants stimulate the Erk/MAP kinase/CREB pathway, leading to cell survival and dynamic long-term adjustment to sensory information.
The report analyzes survival data from 23,000 children diagnosed between 1990 and 1994, showing significant differences in overall cancer survival rates. The Nordic countries had the highest survival figures for four major childhood tumor types, with an average five-year survival rate of 71.8% across all European countries.
A new study published in the Journal of Clinical Oncology found that low-dose interferon therapy did not extend overall or recurrence-free survival in high-risk melanoma patients. The trial involved 674 patients and found that both groups experienced similar rates of disease recurrence and mortality.
Researchers discovered a significant improvement in overall survival for people with Chronic Lymphocytic Leukemia (CLL) after using the antibody rituximab plus fludarabine, increasing progression-free survival by 22% and overall survival by 12%.
A study found that EGFR-positive breast cancer patients had worse disease-free and overall survival rates compared to those with negative EGFR expression. The findings suggest potential prognostic significance of EGFR status in breast cancer.
Researchers found that black patients undergoing surgery had a median survival time 1.8 years less than white patients, with disparities smaller among radiation therapy and non-aggressive therapy groups. The study suggests genetic and environmental factors may contribute to these racial disparities in prostate cancer treatment outcomes.
A study of HIV-infected patients undergoing liver transplantation found improved survival rates compared to HIV-negative patients. Poorer survival was associated with postoperative intolerance, low CD4 counts, and hepatitis C coinfection.
A randomized clinical trial found that endoscopic fetal treatment increased survival to 73 percent for infants with severe CDH, while a comparison group with standard care reached 77 percent. The strongest predictor of survival was the size of the fetus' lungs at diagnosis.
The study found that public access defibrillation increased from 0.82% to 2.05% between 1999 and 2002, with a 50% survival rate for those treated. Over 4,000 people were trained to use the devices, and 457 AEDs were registered.
The study found that patients treated with DOXIL had a median overall survival of 63 weeks, compared to 60 weeks with topotecan. Additionally, DOXIL showed significant advantages in progression-free survival and median PFS for platinum-sensitive patients.
Liver cancer patients who undergo transplantation show improved five-year survival rates, increasing steadily from 25.3% to 61.1% over the past two decades. Regular screening of patients with cirrhosis is essential for early detection and optimal outcomes.
A US study found that liver transplantation significantly improves five-year survival rates for patients with hepatocellular carcinoma (HCC), from 25.3% in the late 1980s to 61.1% in the early 2000s. The study suggests that careful patient selection based on improved criteria may be a key factor in these improvements.
A recent study by the US Department of Veterans Affairs found that Hispanic heart patients had a significant survival advantage compared to their white and African-American counterparts. After adjusting for age and clinical data, Hispanic patients were only about 80% as likely to die as whites or blacks.
The report analyzed data from 22 countries and 42 types of cancer, showing average five-year survival rates ranging from 94% for lip cancer to less than 4% for pancreatic cancer. Regional variations were found, with some Eastern European countries having lower survival rates and western Europe performing better.
A meta-analysis of 14 trials showed no survival benefit with chemotherapy, but adjuvant radiotherapy resulted in a 7% higher mortality rate. Professor Thatcher suggests further research is needed to confirm the result.
The University of Pittsburgh Medical Center has reported significant improvements in intestine transplant survival rates since 1990, with one-year survival increasing to 90% for patients transplanted within the last five years.
Researchers found that a paclitaxel combination improved median and long-term survival rates for patients with early-stage SCLC. The treatment also reduced side effects compared to standard chemotherapy.
Researchers at the University of Pennsylvania identified Pim-2 as a critical enzyme in the survival of cancer cells. The study found that Pim-2 operates independently from the Akt pathway, allowing cancer cells to survive even when starved or deprived of growth factors.
A randomized clinical trial of over 500 women with primary breast cancer found no significant improvement in disease-free survival or overall survival with high-dose chemotherapy and stem cell transplantation. However, time to recurrence was longer for patients who received the treatment.
A new radiotherapy strategy, hyperfractionated accelerated radiotherapy (HART), has been shown to improve survival rates for lung cancer patients. In a phase III multi-site study, chemotherapy followed by HART resulted in a median survival of 21 months, compared to 12 months with standard radiation therapy.
A six-year study found that lung volume reduction surgery improves quality of life and survival rates for patients with upper lobe emphysema who are unable to exercise. The procedure did not show overall survival benefits, but identifying non-beneficial candidates is crucial.
A high-calorie diet may increase chances of surviving bowel cancer for longer, with patients on low and moderate energy intakes around three times as likely to die within five years compared to those on a high intake. Female sex, being under 65, and location of the tumour were found to be factors increasing survival rates.
Researchers at Cedars-Sinai Medical Center found that patients with hereditary BRCA-associated ovarian cancer respond better to chemotherapy, leading to improved survival. The study suggests that platinum-based chemotherapy may be more effective for these patients, and this finding may enable physicians to better plan treatment.
Research from the University of Michigan found that even with prenatal diagnosis, infants with one or more risk factors have a significantly lower chance of survival. However, in utero diagnosis has led to more pregnant women receiving specialty care, resulting in a higher-risk group of patients.
Researchers at Virginia Tech have made significant contributions to understanding bear behavior, including the impact of radio-collars on survival rates and the role of dispersal distance in helping bears evade hunters. Their findings also led to the development of a morphometric-based dichotomous key for age identification.
Researchers have discovered a new six-drug chemotherapy regimen that significantly improves the overall survival rate of Ewing's sarcoma patients to 72% without metastases. The treatment has become routine care for patients with localized disease and has marked a substantial improvement in survival rates.
Two trials found that adjuvant chemotherapy improved recurrence-free survival by 8-11% and overall survival by 5-9%, primarily benefiting patients with unrecognized residual disease. These findings suggest that adjuvant chemotherapy may be most effective in patients with non-optimal surgical staging.
Researchers found that thalidomide therapy works for approximately one year on average, with benefits not being transient. The study's findings offer significant hope for improved survival rates in multiple myeloma patients, an incurable cancer.
Research suggests hatchery steelhead do not harm wild steelhead, but may jeopardize wild chinook survival rates. Studies reveal a strong negative association between hatchery steelhead and wild chinook smolt-to-adult survival.
Recent cancer patient data reveals higher-than-expected five-year to twenty-year relative survival rates across various types of cancer. Period analysis shows more optimistic estimates compared to traditional cohort-based methods.
A new phase III multi-national European trial involving 618 patients with advanced non small-cell lung cancer found that cisplatin and paclitaxel improved survival rates compared to carboplatin and paclitaxel. The study suggests that cisplatin-based chemotherapy remains the preferred standard treatment for lung cancer in Europe.
A recent study by OHSU suggests that hormone replacement therapy (HRT) can lead to improved breast cancer detection and survival rates. The research found that HRT users had a 100% survival rate after six years, compared to an 87% survival rate for non-users.
Research suggests that African-Americans with colon cancer fare equally well when receiving the same treatment as white patients, dispelling long-held theories about innate biological differences. The study found no significant disparities in survival rates between the two groups five years after treatment.